230 related articles for article (PubMed ID: 35685462)
21. Development of an Effective Therapy for Alkaptonuria - Lessons for Osteoarthritis.
Gallagher JA; Dillon JP; Ranganath LR
Rheumatol Immunol Res; 2021 Jun; 2(2):79-85. PubMed ID: 36465977
[TBL] [Abstract][Full Text] [Related]
22. Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment.
Ranganath LR; Milan AM; Hughes AT; Dutton JJ; Fitzgerald R; Briggs MC; Bygott H; Psarelli EE; Cox TF; Gallagher JA; Jarvis JC; van Kan C; Hall AK; Laan D; Olsson B; Szamosi J; Rudebeck M; Kullenberg T; Cronlund A; Svensson L; Junestrand C; Ayoob H; Timmis OG; Sireau N; Le Quan Sang KH; Genovese F; Braconi D; Santucci A; Nemethova M; Zatkova A; McCaffrey J; Christensen P; Ross G; Imrich R; Rovensky J
Ann Rheum Dis; 2016 Feb; 75(2):362-7. PubMed ID: 25475116
[TBL] [Abstract][Full Text] [Related]
23. Identification of 11 Novel Homogentisate 1,2 Dioxygenase Variants in Alkaptonuria Patients and Establishment of a Novel LOVD-Based HGD Mutation Database.
Zatkova A; Sedlackova T; Radvansky J; Polakova H; Nemethova M; Aquaron R; Dursun I; Usher JL; Kadasi L
JIMD Rep; 2012; 4():55-65. PubMed ID: 23430897
[TBL] [Abstract][Full Text] [Related]
24. Alkaptonuria in Turkey: Clinical and molecular characteristics of 66 patients.
Kisa PT; Gunduz M; Dorum S; Uzun OU; Cakar NE; Yildirim GK; Erdol S; Hismi BO; Tugsal HY; Ucar U; Gorukmez O; Gulten ZA; Kucukcongar A; Bulbul S; Sari I; Arslan N
Eur J Med Genet; 2021 May; 64(5):104197. PubMed ID: 33746036
[TBL] [Abstract][Full Text] [Related]
25. Analysis of the Phenotype Differences in Siblings with Alkaptonuria.
Zatkova A; Olsson B; Ranganath LR; Imrich R
Metabolites; 2022 Oct; 12(10):. PubMed ID: 36295892
[TBL] [Abstract][Full Text] [Related]
26. Homogentisic acid induces autophagy alterations leading to chondroptosis in human chondrocytes: Implications in Alkaptonuria.
Galderisi S; Milella MS; Rossi M; Cicaloni V; Rossi R; Giustarini D; Spiga O; Tinti L; Salvini L; Tinti C; Braconi D; Millucci L; Lupetti P; Prischi F; Bernardini G; Santucci A
Arch Biochem Biophys; 2022 Mar; 717():109137. PubMed ID: 35090868
[TBL] [Abstract][Full Text] [Related]
27. Identification of Potential Inhibitors for the Treatment of Alkaptonuria Using an Integrated In Silico Computational Strategy.
Zaib S; Rana N; Hussain N; Ogaly HA; Dera AA; Khan I
Molecules; 2023 Mar; 28(6):. PubMed ID: 36985595
[TBL] [Abstract][Full Text] [Related]
28. Homogentisic acid induces aggregation and fibrillation of amyloidogenic proteins.
Braconi D; Millucci L; Bernini A; Spiga O; Lupetti P; Marzocchi B; Niccolai N; Bernardini G; Santucci A
Biochim Biophys Acta Gen Subj; 2017 Feb; 1861(2):135-146. PubMed ID: 27865997
[TBL] [Abstract][Full Text] [Related]
29. Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria.
Milan AM; Hughes AT; Davison AS; Khedr M; Rovensky J; Psarelli EE; Cox TF; Rhodes NP; Gallagher JA; Ranganath LR
Sci Rep; 2019 Jul; 9(1):10024. PubMed ID: 31296884
[TBL] [Abstract][Full Text] [Related]
30. Reduced primary cilia length and altered Arl13b expression are associated with deregulated chondrocyte Hedgehog signaling in alkaptonuria.
Thorpe SD; Gambassi S; Thompson CL; Chandrakumar C; Santucci A; Knight MM
J Cell Physiol; 2017 Sep; 232(9):2407-2417. PubMed ID: 28158906
[TBL] [Abstract][Full Text] [Related]
31. Homogentisic acid is not only eliminated by glomerular filtration and tubular secretion but also produced in the kidney in alkaptonuria.
Ranganath LR; Milan AM; Hughes AT; Khedr M; Davison AS; Shweihdi E; Norman BP; Hughes JH; Bygott H; Luangrath E; Fitzgerald R; Psarelli EE; van Kan C; Laan D; Olsson B; Rudebeck M; Mankowitz L; Sireau N; Arnoux JB; Le Quan Sang KH; Jarvis JC; Genovese F; Braconi D; Santucci A; Zatkova A; Glasova H; Stančík R; Imrich R; Rhodes NP; Gallagher JA
J Inherit Metab Dis; 2020 Jul; 43(4):737-747. PubMed ID: 31609457
[TBL] [Abstract][Full Text] [Related]
32. A molecular spectroscopy approach for the investigation of early phase ochronotic pigment development in Alkaptonuria.
Bernini A; Petricci E; Atrei A; Baratto MC; Manetti F; Santucci A
Sci Rep; 2021 Nov; 11(1):22562. PubMed ID: 34799606
[TBL] [Abstract][Full Text] [Related]
33. Oxidative stress and mechanisms of ochronosis in alkaptonuria.
Braconi D; Millucci L; Bernardini G; Santucci A
Free Radic Biol Med; 2015 Nov; 88(Pt A):70-80. PubMed ID: 25733348
[TBL] [Abstract][Full Text] [Related]
34. Relationship Between Serum Concentrations of Nitisinone and Its Effect on Homogentisic Acid and Tyrosine in Patients with Alkaptonuria.
Olsson B; Cox TF; Psarelli EE; Szamosi J; Hughes AT; Milan AM; Hall AK; Rovensky J; Ranganath LR
JIMD Rep; 2015; 24():21-7. PubMed ID: 25772318
[TBL] [Abstract][Full Text] [Related]
35. Founder effects of the homogentisate 1,2-dioxygenase (HGD) gene in a gypsy population and mutation spectrum in the gene among alkaptonuria patients from India.
Danda S; Mohan S; Devaraj P; Dutta AK; Nampoothiri S; Yesodharan D; Phadke SR; Jalan AB; Thangaraj K; Verma IC; Danda D; Jebaraj I
Clin Rheumatol; 2020 Sep; 39(9):2743-2749. PubMed ID: 32212000
[TBL] [Abstract][Full Text] [Related]
36. Revisiting Quantification of Phenylalanine/Tyrosine Flux in the Ochronotic Pathway during Long-Term Nitisinone Treatment of Alkaptonuria.
Ranganath LR; Hughes AT; Davison AS; Khedr M; Imrich R; Rudebeck M; Olsson B; Norman BP; Bou-Gharios G; Gallagher JA; Milan AM
Metabolites; 2022 Sep; 12(10):. PubMed ID: 36295821
[TBL] [Abstract][Full Text] [Related]
37. Method development and validation for analysis of phenylalanine, 4-hydroxyphenyllactic acid and 4-hydroxyphenylpyruvic acid in serum and urine.
Hughes AT; Milan AM; Shweihdi E; Gallagher J; Ranganath L
JIMD Rep; 2022 Jul; 63(4):341-350. PubMed ID: 35822095
[TBL] [Abstract][Full Text] [Related]
38. Nutritional interventions for patients with alkaptonuria: A minireview.
Imrich R; Zatkova A; Lukacova O; Sedlakova J; Zanova E; Vlcek M; Penesova A; Radikova Z; Havranova A; Ranganath L
Endocr Regul; 2023 Jan; 57(1):61-67. PubMed ID: 36966367
[TBL] [Abstract][Full Text] [Related]
39. Alkaptonuria: Current Perspectives.
Zatkova A; Ranganath L; Kadasi L
Appl Clin Genet; 2020; 13():37-47. PubMed ID: 32158253
[TBL] [Abstract][Full Text] [Related]
40. Interference of hydroxyphenylpyruvic acid, hydroxyphenyllactic acid and tyrosine on routine serum and urine clinical chemistry assays; implications for biochemical monitoring of patients with alkaptonuria treated with nitisinone.
Curtis SL; Norman BP; Milan AM; Gallagher JA; Olsson B; Ranganath LR; Roberts NB
Clin Biochem; 2019 Sep; 71():24-30. PubMed ID: 31228435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
